General Information
Protein Induced by Vitamin K Kusavapo kana Antagonist-II (PIVKA-II), inozivikanwawo seDes-γ-carboxy-prothrombin (DCP), imhando isina kujairika yeprothrombin.Kazhinji, prothrombin's gumi glutamic acid zvisaririra (Glu) mu γ-carboxyglutamic acid (Gla) domain panzvimbo 6, 7, 14, 16, 19, 20,25, 26, 29 uye 32 ari γ-carboxylated kuGlaita -K inotsamira γ- glutamyl carboxylase muchiropa uye yozobudiswa mu plasma.Mune varwere vane hepatocellular carcinoma (HCC), γ-carboxylation yeprothrombin inokanganisa kuitira kuti PIVKA-II iumbwe panzvimbo yeprothrombin.PIVKA-II inoonekwa seyakajeka biomarker yakanangana neHCC.
Pair Recommendation | CIA (Kutora-Kuonekwa): 1E5-1 ~ 1D6-10 1E5-1 ~ 1E6-7 |
Kuchena | > 95%, yakatarwa neSDS-PEJI |
Buffer Formulation | 20 mM PB, 150 mM NaCl, 0.1% Proclin 300, pH7.4 |
Storage | Chengetedza pasi pemamiriro ekudzivirira pa -20 ℃ kusvika -80 ℃ paunogamuchira. Nekuchengetedza kwenguva refu, ndapota aliquot uye chengeta.Dzivisa kudzokororwa nechando uye kunyunguduka kutenderera. |
Product Name | Katsi.Aihwa | Clone ID |
PIVKA-Ⅱ | AB0009-1 | 1F4-5 |
AB0009-2 | 1E5-1 | |
AB0009-3 | 1D6-10 | |
AB0009-4 | 1E6-7 |
Ongorora: Bioantibody inogona kugadzirisa huwandu maererano nezvaunoda.
1.Matsueda K , Yamamoto H , Yoshida Y , et al.Hepatoid carcinoma yerwatata inogadzira mapuroteni anokonzerwa nevhitamini K kusavapo kana antagonist II (PIVKA-II) uye α-fetoprotein (AFP) [J].Chinyorwa cheGastroenterology, 2006, 41(10):1011-1019.
2.Viggiani, Valentina, Palombi, 等.Mapuroteni anokonzerwa nevhitamini K kusavapo kana antagonist-II (PIVKA-II) yakanyatsowedzera muItaly hepatocellular carcinoma varwere.[J].Scandinavian Journal yeGastroenterology, 2016.
3.Simundic AM .Kurudziro inoshanda yekuongorora kwenhamba uye kuratidzwa kwedata muBiochemia Medica magazini[J].Biochemia Medica, 2012, 22(1).
4.Tartaglione S , Pecorella I , Zarrillo SR , et al.Protein Induced na Vitamin K Kusavapo II (PIVKA-II) seanogona serological biomarker mupancreatic cancer: chidzidzo chemutyairi [J].Biochemia Medica, 2019, 29(2).